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Abstract
AIM: Evaluation of the safety and efficacy of pulmonary veins isolation in patients with paroxysmal atrial fibrillation 
(AF) using two new different technologies, cryoballoon (CB) ablation and radiofrequency ablation with contact force 
(CF)-sensing catheters.
METHODS: Prospective single-center evaluation, carried out from January 2016 to June 2018 in Critical Care 
Medicine Department – Cairo University, comparing CF radiofrequency (Thermocool® SmartTouch, Biosense 
Webster, Inc.) (CF group) with CB ablation (Arctic Front Advance 28 mm CB, Medtronic, Inc.) (CB group), in 
regards to procedural safety and efficacy, as well as recurrence at 12 months. Overall, 50 consecutive patients were 
enrolled (25 in each group).
RESULTS: The characteristics of patients of both the groups were similar (46.9 ± 11.2 years, the proportion of 
women 36%, mean documented AF duration 3 ± 2.3 years, mean CHA2DS2-VASc score 1.4 ± 1.3, and mean HAS-
BLED 1.4 ± 0.6). Duration of the procedure was significantly lower in the CB group (171.7 ± 15.24 vs. 199.3 ± 18.94 
min, p = 0.002), with a longer duration of fluoroscopy and X-ray exposure in the CB group than the CF group but 
statistically non-significant difference (58.60 ± 11.57 vs. 48.7 ± 13.86 min and 6273 ± 4934 cGy cm² vs. 6853 ± 5069 
cGy cm², p = 0.1 and p = 0.2, respectively). Overall complication rate was similar in both groups: 2 (8%) in each 
group. At 12 months, AF recurrence occurred in 7 patients (28%) in the CF group and in 9 patients (36%) in the CB 
group (log rank p = 0.682).
CONCLUSION: Pulmonary vein isolation using CF-guided RF and second-generation CB leads to comparable 
single-procedure arrhythmia-free survival at up to 12 months with similar overall complication rate.
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Introduction
Atrial fibrillation (AF) is the most common 
sustained supraventricular tachyarrhythmia [1]. Catheter 
ablation strategies for the treatment of AF have been in 
a process of continuous development since 1996, and 
catheter ablation is now regarded as an effective and 
safe therapeutic option. Pulmonary vein isolation (PVI) 
is the cornerstone of catheter ablation techniques for 
the treatment of paroxysmal AF (PAF), with significantly 
improved efficacy compared to antiarrhythmic drugs [2], [3] 
However, AF recurrence after a single procedure remains 
relatively frequent and in most of cases is related to 
PV reconnections [4]. This may reflect the difficulty in 
achieving effective transmural, continuous, and long-
lasting lesions when performing PVI [5], [6]. Newer 
technologies are being developed with efforts to improve 
outcomes in patients undergoing AF ablations. The 
contact force (CF) between catheter tip and PVs tissue has 
been shown to be a major influencing factor in achieving 
effective and continuous tissue lesions [7], [8], [9], [10]. 
Accordingly, novel technologies for AF catheter ablation 
have recently focused on the optimization of the contact 
between catheter tip and target tissue. On the one 
hand, the CF-sensing technology has been recently 
developed, allowing continuous CF monitoring during 
ablation [11]. On the other hand, second generation of 
cryoballoon (CB), the Arctic Front AdvanceTM, has been 
developed to optimize lesions in various settings of PV 
anatomies [12], [13], [14]. However, the question arises 
in which PAF patients whether PVI can be done using 
radiofrequency ablation with CF sensing catheter or with 
CB ablation. In the present study, we sought to compare 
the safety and efficacy of CF-sensing RF catheters with 
second-generation CB catheter in the setting of PAF 
catheter ablation.
Methods
Study type, study population, and data 
collection
This is a prospective non-randomized 
controlled clinical trial that was conducted during the 
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period between January 2016 and June 2018 in Critical 
Care Medicine Department – Cairo University. The 
primary endpoint of this study is to compare the safety 
and efficacy of catheter ablation of PAF using two 
different technologies (RF ablation using CF catheters 
vs. cryoballoon ablation) as a first experience with 
those two new technologies in our center. Secondary 
end points consisted of (1) freedom from AF or atrial 
flutter/tachycardia lasting >30 s at 12 months after a 
3-month blanking period, following a single ablation 
procedure without the use of antiarrhythmic therapy 
(2) determinants of fluoroscopy time, and (3) types 
and frequencies of procedure-related complications. 
Our study design involved 25 patients in each group. 
Patients were eligible if they presented with PAF 
refractory to at least one antiarrhythmic drug from 
Class I or III undergoing first PVI procedure. Exclusion 
criteria were in need of additional lines (i.e., roof and 
mitral isthmus) or ablation of complex-fractionated 
electrograms during the procedure. Importantly, 
patient selection for one or the other energy group was 
not made depending on the patient’s characteristics 
(i.e., PV anatomy) but based on physician discretion 
performing the ablation procedure. Specifically, each 
electrophysiology physician used always the same 
ablation energy (either RF or cryothermal) for all his 
AF ablations, regardless of PV anatomy. All patients 
provided an informed written consent before the 
procedure.
Ablation procedure details: Common 
Elements between CF and CB Groups
Transesophageal echocardiography was 
done 24–48 h before the procedure to determine left 
atrial (LA) dimensions and to exclude the presence of 
a potential LA thrombus. Vitamin-K antagonists were 
not interrupted before the procedure with INR <3. 
New oral anticoagulants were not interrupted before 
the procedure. All procedures were performed under 
a mild conscious or deep sedation depending on 
the physician performing the procedure. A decapolar 
catheter was positioned in the coronary sinus, through 
a transfemoral venous access. A single or double 
transseptal puncture was performed under fluoroscopic 
guidance. A bolus of unfractionated heparin (UFH) 
was administered immediately after the transseptal 
puncture and infusion was titrated to maintain activated 
clotting time (ACT) of 300–350 s for the duration of 
the procedure. No esophageal monitoring was done 
during the procedure. ACT was then repeated every 
30 min and UFH was given accordingly to maintain the 
measurements within target. At the end of procedure, 
protamine was given, at operator’s discretion, to 
reverse the effect of heparin. Catheters were removed 
and hemostasis was ensured. Procedure time (from 
skin puncture to removal of sheaths) and fluoroscopy 
time were recorded.
Specific procedural details: CF group
A circumferential mapping catheter (CMC; 
LassoTM; Biosense Webster) was introduced into 
the LA using an 8.5 Fr long sheath. The ablation 
catheter was advanced into the LA either sequentially 
after removing the CMC (in case of single transseptal 
puncture) or simultaneously with the CMC (in case of 
double transseptal punctures). The ablation catheter 
and the CMC were used to collect LA geometry using 
the electroanatomic mapping (EAM) system. The 
ablation strategy consisted of PVI using two wide 
antral circumferential RF ablations across ipsilateral 
PVs, without additional adjunctive LA ablation. Power 
controlled RF ablation lesions were delivered with 
30–35Wpower (flow rate, 17–20 mL/min); the endpoint 
was elimination of the local bipolar EGM with 20–40 
s lesions, or with force-time integral (FTI) >400 g s. 
A lower power 20–25 W (flow rate, 17 mL/min) and 
duration settings were used for ablation on the posterior 
LA wall close to the esophagus. CF data were available 
to the operator throughout the procedure. The aim 
was to achieve a mean CF of at least 10 g during RF 
application. The upper limit defined was 50 g force [7]. 
PVI was first performed anatomically, the Lasso 
catheter being used only after completion of anatomic 
PVI to confirm full PV disconnection. This was done 
by testing both entrance and exit block (bidirectional 
block). In the event, complete disconnection was not 
achieved (failure of either exit or entrance block), PVI 
was completed with Lasso guidance to eliminate all 
points of residual PV connection. Carina ablations were 
performed when PV isolation could not be achieved 
with antral isolation. Typically carina ablation targeted 
the earliest potential for both ipsilateral PVs identified at 
the carina. At the end of the procedure, a waiting period 
of at least 20 min was performed, to assess for dormant 
LA–PV connections.
Specific procedural details: CB group
Pulmonary vein angiography was done for 
all patients after the transseptal puncture to assess 
PVs number and anatomy. A 14-Fr deflectable sheath 
(FlexCath, Medtronic) was advanced into the LA 
through the transseptal puncture. Then, the Arctic Front 
AdvanceTM balloon was introduced into the sheath, 
inflated, and advanced to the ostium of each PV. 
Before cryoenergy delivery, the occlusion of each PV 
was assessed with a venous angiography. Ablation of 
PV antra was performed with two applications of 240 s 
per vein. Continuous monitoring of the phrenic nerve 
during ablation of the right PVs was systematically 
performed by pacing the right phrenic nerve with a 
quadripolar catheter in the superior vena cava. PVI 
was either assessed continuously using the circular 
Achieve Catheter (Medtronic) during CB freezing or 
traditionally using a CMC (Lasso, Biosense Webster) 
after two applications. If the PV remained connected, 
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additional applications were performed using different 
angulations. PVI was finally checked 20 min after the 
last CB ablation.
Standardized follow-up
A transthoracic echocardiography was 
performed immediately after the procedure and before 
hospital discharge. Patients were followed for a total 
of 12 months. Patients were evaluated before hospital 
discharge, as well as at 1, 3, 6, 9, and 12 months after 
the procedure. Information collected during follow-up 
included clinical symptoms, a 12-lead electrocardiogram 
(ECG) and a 24-h Holter monitoring at each visit. A 
blanking period of 3 month has been chosen in this study 
during which antiarrhythmic drugs were maintained. 
After the blanking period, all antiarrhythmic drugs 
were stopped. If there was documented recurrence of 
symptomatic AF after this time interval and the patient 
required antiarrhythmic drug therapy, a previously 
ineffective but tolerated Class I or Class III drug was 
the preferred option. Anticoagulation strategy after the 
first 3 months was based on the CHA2DS2Vasc and 
HAS-BLED scores [15].
Procedural endpoint
Procedural endpoint was PV isolation 
confirmed by entry and exit block after a waiting time 
of 20 min. The specific differences of the two used 
therapeutic approaches are described above.
Study endpoints
The long-term efficacy endpoint was freedom 
from any atrial arrhythmia lasting more than 30 s for up to 
12 months after a single procedure. This was achieved 
by Holter monitoring at 1, 3, 6, 9, and 12 months or by 
12-lead ECG in the case of symptomatic palpitation at 
clinical visits. Patients with recurrence of AF after the 
blanking period and in the absence of antiarrhythmic 
drugs were classified as having a relapse. The safety 
endpoint was a comparison of significant adverse 
events between groups.
Statistical methods
Data were coded and entered using the 
statistical package SPSS version 25. Data were 
summarized using mean and standard deviation for 
quantitative variables and frequencies (number of 
cases) and relative frequencies (percentages) for 
categorical variables. Comparisons between groups 
were done using unpaired t-test. For comparing 
categorical data, Chi-square test was performed. Exact 
test was used instead when the expected frequency is 
< 5. Correlations between quantitative variables were 
done using Pearson correlation coefficient. p = 0.05 
were considered as statistically significant.
Results
Patient characteristics
Population characteristics are detailed in 
Table 1. Overall, 50 patients were included: 25 in 
the CF group underwent PVI using the Thermocool 
SmartTouchTM catheter and 25 in the CB group. 
Cavotricuspid isthmus ablation was performed in 2 
patients (8%) of the CF group. The mean age of patients 
was 46.9 + 11.72 years. The proportion of women was 
36%; the LA size in the parasternal long axis was 40.5 ± 
4.75 mm. Mean duration of documented AF was 3 ± 2.3 
years and was not significantly different between the 
two groups. Mean CHA2DS2-VASc score 1.4 ± 1.3 and 
mean HAS-BLED 1.4 ± 0.6 without significant difference 
between both groups. Overall, no significant baseline 
differences were observed between the CF and CB. 
All the patients continued on antiarrhythmic and on 
anticoagulation therapy for 3 months post-ablation.
Table 1: Baseline characteristics of patients
Demographic data All n=50 Group 1 (CB) 
n=25 (50%)
Group 2 (CF) 
n=25 (50%)
p-value
*Age (years) 46.9 ± 11.7 47.9 ± 11.6 45.9 ± 12.35 0.714
*Gender (F)* (%) 18 (36) 10 (40) 8 (32) >0.05
*Hypertension 11 (22) 6 (24) 5 (20) >0.05
*DM 12 (24) 7 (28) 5 (20) >0.05
*CAD 3 (6) 2 (8) 1(4) >0.05
*HF 3 (6) 1 (4) 2(8) >0.05
*Asthma 1 (2) 0 (0) 1 (4) >0.05
*LAD 4.05 ± 0.475 4.1 ± 0.38 4.09 ± 0.57 0.716
*LVEF% 61.65 ± 6.7 61.2 ± 5.73 62.1 ± 7.8 0.773
*CHA2DS2-VASC score 1.4 ± 1.3 1.5 ± 1.3 1.3 ± 1.3 0.308
*HAS-BLED 1.4 ± 0.6 1.5 ± 0.6 1.4 ± 0.5 0.243
*AF duration (years) 3 ± 2.3 3 ± 2.5 3 ± 2.1 0.7
AF: Atrial fibrillation, CF: Contact force, CB: Cryoballoon, LVEF: Left ventricular ejection fraction.
Procedural results
Procedural data are detailed in Table 2. All 
PVs in both groups were successfully isolated during 
the procedure. No complementary RF applications 
were needed to achieve complete PVI in the CB group. 
Duration of the procedure was significantly lower in 
the CB group (171.7 ± 15.24 vs. 199.3 ± 18.94 min, 
p = 0.002), however, with a longer duration of fluoroscopy 
and X-ray exposure in the CB group than the CF group 
but statistically non-significant difference (58.60 ± 11.57 
vs. 48.7 ± 13.86 min and 6273 ± 4934 cGy cm² vs. 6853 
± 5069 cGy cm², p = 0.1 and p = 0.2, respectively). Mean 
CF observed in the CF group was 18.4 g ± 35.
Table 2: Procedure data in both groups
Procedure data CB group CF group p-value
Time from puncture to transseptal (min) 26.80 ± 6.32 17.6 ± 4.43 0.001
Procedure time (min) 171.70 ± 15.24 199.3 ± 18.94 0.002
Time of mapping PVs/LA (min) 27.90 ± 6.3 27.6 ± 7.07 0.921
Fluoroscopy time (min) 58.60 ± 11.57 48.7 ± 13.86 0.100
X-ray exposure(cGy cm2) 6273 ± 4934 6853 ± 5069 0.22
CF: Contact force, CB: Cryoballoon, LA: Left atrial.
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Periprocedural complications
The total number of complications in both 
groups was similar: 2 (8%) in each group. Transient 
phrenic nerve palsy occurred in one patient (4%) of the 
CB group with normal diaphragmatic function at the end 
of the procedure. No patient died in either group from 
a procedural complication but severe complications 
occurred in 3 patients (6%). Pericardial effusion 
and tamponade due to perforation of the left atrial 
appendage (LAA) occurred only in one patient in the CF 
group and this required surgical repair of the LAA (for 
this patient, PVI was already achieved). Entrapment of 
circular mapping catheter into the mitral valve chordae 
occurred in one patient in the CF group which required 
surgical intervention (for this patient, PVI was already 
achieved). Embolic stroke occurred in one patient of the 
CB group post ablation, diagnosed by MRI brain with 
diffusion.
Twelve-month follow-up
All patients were followed up for 12 months 
after the procedure.
AF recurrence occurred in 7 (28%) patients in 
the CF group and in 9 (36%) patients in the CB group. 
All recurrences were in the form of AF except for one 
patient (in CF group) whose recurrence was in the form 
of atrial flutter.
Older patients were more likely to have AF 
recurrence than those with younger age (55.00 + 7.85 
vs. 42.54 + 11.30, p = 0.019). Patients with higher left 
ventricular ejection fraction (LVEF)% were less likely 
to have AF recurrence than those with lower LVEF% 
(64.46 + 5.52 vs. 56.43 + 5.68, p = 0.007). Furthermore, 
our study showed that recurrence in blanking period 
(first 3 months post-procedure) was found to precede 
most cases of later recurrence (p = 0.017).
Discussion
AF represents an important public health 
problem. Patients with AF have an increased long-term risk 
of stroke, heart failure, and all-cause mortality [16], [17], 
[18]. Catheter ablation has emerged as effective therapy 
for AF, especially when antiarrhythmic drugs (AADs) fail. 
Catheter ablation (CA) for symptomatic drug-refractory, 
PAF is a Class I/A treatment indication in the current 
guidelines [19], [20], [21]. When CA is necessary, PVI 
is the cornerstone of ablation for PAF and RF, CA is 
the traditional method of ablation [22]. The rationale for 
better RF lesions using higher CF is a larger electrode-
tissue contact area, allowing improved RF energy 
delivery to the myocardium. Subsequently, new RF 
catheters have embedded force-sensing technologies 
(Thermocool SmartTouchTM and TacticathTM) providing 
real-time CF monitoring, allowing for electrode-tissue 
contact optimization. During AF ablation procedures, 
CF monitoring permitted a reduction of PV chronic 
reconnection and an improvement of clinical outcomes 
by targeting a CF of at least 10 g (if possible 20 g) and 
a FTI .400 g s for each RF application [10], [23], [24]. 
Finally, CF monitoring may increase procedure safety 
by avoiding high CF values, which are at higher risk of 
steam pop and cardiac perforation [7], [25]. On the other 
hand, AF ablation using cryotherapy has also evolved 
recently with dramatic CB improvements. Compared 
with the first generation CB (Arctic FrontTM), the 
second-generation CB (Arctic Front AdvanceTM) has 
twice as many injection ports (8), and these have been 
positioned more distally on the catheter’s shaft resulting 
in a larger and more uniform zone of freezing on the 
CB surface. This resulted in improved procedural data 
(procedure duration, fluoroscopy time, time to PVI) 
compared with the first-generation CB [26], [27], and in 
better clinical outcomes.
To the best of our knowledge, the present 
study is the first prospective, trial in Egypt evaluating 
the efficacy and safety of catheter ablation using 
two different technologies, RFCA with CF sensing 
catheters and CBCA for PAF patients’ refractory to 
medical treatment. Specifically, the study examined 
the preferred ablation method for PVI as a second line 
treatment strategy in symptomatic PAF patients.
In this single center study, we demonstrated 
that new CF-sensing RF catheters and second-
generation CB have comparable efficacy in the setting 
of PAF ablation. A comparable proportion of patients 
in both groups (72% in the CF group vs. 64% in the 
CB group) remained free from any atrial arrhythmia 
at 12 months after a single ablation procedure, free 
of antiarrhythmic drugs. The overall complication 
rates were equivalent with both technologies, but 
cryoablation led more frequently to transient phrenic 
nerve palsy, and RF ablation led more frequently to 
severe non-lethal complications. Procedure duration 
was slightly longer using RF than using cryoablation; 
these findings were already reported previously and 
probably account for the time required to create the 
three dimension (3D) EAM and to perform the point-
by-point isolation of the PVs with the RF ablation 
catheters. If the use of CF-sensing RF catheter or 
second-generation CB catheter should be preferred 
over older models, the choice of either of the ablation 
energies (RF or cryothermal) for PAF ablation often 
depends on the operators’ skills and habits, and on 
available material and associated costs. Our results 
suggest that both RF with CF-sensing and cryoenergy 
lead to comparable outcomes in non-selected 
patients, with a similar overall complication rate. 
Therefore, in case of PAF ablation, this study does 
not provide clues for a clear preference between RF 
and cryoablation.
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Limitations
We were very strict about inclusion and 
exclusion criteria, good selection of homogeneous 
patient criteria in both groups, and eradication of all 
potential biases that can affect our results; however, 
this study has several limitations. First, this is not a 
randomized trial and inclusion of the patients for one or 
the other group is potentially subject to significant bias.
Second, different operators and the presence 
of trainee with different experiences may affect 
recurrence rate, procedure duration, fluoroscopy time, 
and complication rate. Thirdly, follow-up was performed 
using systematic 24 h-Holter ECGs and additional 
24 h-Holter ECGs in case of symptoms. This method 
may underestimate recurrence rates compared with 
implantable loop recorders. Fourth, the lack of CT 
angiography of left atrium or MRI of left atrium before 
ablation and its merging with 3D mapping system or 
during CB ablation was associated with prolonged total 
procedure duration, fluoroscopy time, and radiation 
exposure. Finally, this study is our first Egyptian 
experience with CF sensing catheters (Smart TouchTM) 
and CB ablation and we were in the growing curve of 
cryoablation.
Conclusion
The treatment of patients with symptomatic 
PAF who are refractory to antiarrhythmic drug therapy 
with catheter ablation became well established and 
seems to be safe and effective with RF or CB. By 
comparison, the CB procedure was significantly faster 
and less complex, which are important considerations 
when evaluating the preferred ablation method. The 
radiation exposure was higher in the CB group but 
remained in a reasonable range when compared with 
RF cohort. More data are necessary to determine the 
preferred energy source for catheter ablation of PAF. 
At the moment, if the use of CF-sensing RF catheter 
or second-generation CB catheter should be preferred 
over older models, the choice of either of the ablation 
energies (RF or cryothermal) for PAF ablation often 
depends on the operators’ skills and habits, and on 
available material and associated costs.
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